全文获取类型
收费全文 | 1276912篇 |
免费 | 99777篇 |
国内免费 | 1989篇 |
专业分类
耳鼻咽喉 | 18428篇 |
儿科学 | 44352篇 |
妇产科学 | 35009篇 |
基础医学 | 182182篇 |
口腔科学 | 33582篇 |
临床医学 | 111252篇 |
内科学 | 258215篇 |
皮肤病学 | 28021篇 |
神经病学 | 100380篇 |
特种医学 | 51212篇 |
外国民族医学 | 660篇 |
外科学 | 196406篇 |
综合类 | 27049篇 |
现状与发展 | 1篇 |
一般理论 | 377篇 |
预防医学 | 95737篇 |
眼科学 | 27916篇 |
药学 | 94768篇 |
2篇 | |
中国医学 | 2422篇 |
肿瘤学 | 70707篇 |
出版年
2018年 | 13136篇 |
2017年 | 9965篇 |
2016年 | 10906篇 |
2015年 | 12371篇 |
2014年 | 17165篇 |
2013年 | 26213篇 |
2012年 | 36023篇 |
2011年 | 38060篇 |
2010年 | 22802篇 |
2009年 | 21810篇 |
2008年 | 36640篇 |
2007年 | 39250篇 |
2006年 | 39511篇 |
2005年 | 38452篇 |
2004年 | 37606篇 |
2003年 | 36451篇 |
2002年 | 35803篇 |
2001年 | 63997篇 |
2000年 | 66499篇 |
1999年 | 56411篇 |
1998年 | 15128篇 |
1997年 | 13755篇 |
1996年 | 14195篇 |
1995年 | 13453篇 |
1994年 | 12766篇 |
1993年 | 11791篇 |
1992年 | 44554篇 |
1991年 | 43464篇 |
1990年 | 42221篇 |
1989年 | 40117篇 |
1988年 | 36900篇 |
1987年 | 36238篇 |
1986年 | 33622篇 |
1985年 | 32284篇 |
1984年 | 24141篇 |
1983年 | 20273篇 |
1982年 | 11725篇 |
1981年 | 10695篇 |
1980年 | 9516篇 |
1979年 | 21344篇 |
1978年 | 14824篇 |
1977年 | 12532篇 |
1976年 | 11693篇 |
1975年 | 12624篇 |
1974年 | 14661篇 |
1973年 | 14119篇 |
1972年 | 12946篇 |
1971年 | 11730篇 |
1970年 | 11053篇 |
1969年 | 10024篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Bielik Peter Bonczek Ondřej Krejčí Přemysl Zeman Tomáš Izakovičová-Hollá Lydie Šoukalová Jana Vaněk Jiří Vojtěšek Bořivoj Lochman Jan Balcar Vladimir J. Šerý Omar 《Clinical oral investigations》2022,26(12):7045-7055
Clinical Oral Investigations - The aim of this study was the analysis of WNT10A variants in seven families of probands with various forms of tooth agenesis and self-reported family history of... 相似文献
102.
103.
T.-Y. Huang Y.-J. Hsia M.-Y. Sung Y.-T. Wu P.-C. Hsu 《International journal of oral and maxillofacial surgery》2021,50(8):1100-1106
Zygomatic implant treatment is widely applied for severe maxillary atrophy to help rehabilitate the maxillary dentition. This retrospective study was performed to evaluate the actual radiographic bone–implant contact (rBIC) lengths of zygomatic implants. The records of 28 patients who underwent zygomatic implant surgery and subsequent follow-up examinations between August 2013 and September 2018 in the Department of Oral and Maxillofacial Surgery, Taipei Tzu Chi Hospital were reviewed. The surgeries were performed by a single surgeon using the same treatment protocol. All patients had a computed tomography scan at 1 year after the surgery. Using three-dimensional imaging software, an investigator measured the rBIC lengths of 66 implants and documented their clinical status. The implant survival rate was 100%. The mean rBIC length was significantly longer in male patients than in female patients (20.80 ± 5.88 mm versus 17.79 ± 6.34 mm; P = 0.028). The mean rBIC length of double zygomatic implants was significantly longer when compared to that of single implants (21.11 ± 6.23 mm versus 17.75 ± 5.85 mm; P = 0.027). This article is novel in reporting the exact rBIC lengths of zygomatic implants in a clinical setting. The results showed that zygomatic implants are a viable treatment modality for full-mouth rehabilitation. 相似文献
104.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
105.
106.
107.
108.
In both adults and children with diabetes, technologies such as continuous subcutaneous insulin infusion using insulin pumps and continuous glucose monitoring can help improve diabetes control, reduce hypoglycaemia and improve quality of life. Access to these technologies in the UK is very variable. Some technologies are recommended by the National Institute for Health and Care Excellence, while others have not been appraised, and new technologies are emerging all the time. Additionally, different guidelines for adults and children further complicate access to diabetes technology in the transition from paediatric to adult care. Against this background, Diabetes UK and NHS England have brought together a multidisciplinary group of experts, including clinicians and people with diabetes, to develop this consensus guideline, combining the different technologies into a common pathway to aid clinical and policy decision‐making. We created a pathway that supports the incremental addition of technology as monotherapy and then dual therapy in the same way that we incrementally add in therapeutic agents to support people with Type 2 diabetes to achieve their personalized glycaemic targets. The pathway emphasizes the importance of structured education, specialist support and appropriate access to psychological therapies, as essential pillars for optimized use of diabetes‐related technology, and recommends the re‐evaluation of its use when the individual is unable either to use the technology appropriately or to achieve the intended outcomes. This pathway is endorsed by UK‐wide clinical and patient associations and we recommend that providers and commissioners use it to ensure the right individual with diabetes has access to the right technology in a timely way to help achieve better outcomes. 相似文献
109.